Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Pharmaceuticals Other
|SAVA||Cassava Sciences, Inc.||-6.90%||49.69||0.0%||$331.13m|
|VRX||Valeant Pharmaceuticals International, Inc.||0.25%||28.50||14.1%||$167.70m|
|PRGO||Perrigo Co. Plc||-1.63%||44.73||6.9%||$131.09m|
|HZNP||Horizon Therapeutics Plc||-0.80%||112.08||5.5%||$127.22m|
|JAZZ||Jazz Pharmaceuticals Plc||2.54%||140.70||2.1%||$100.37m|
|UTHR||United Therapeutics Corp.||-0.28%||187.07||14.0%||$64.01m|
|BHC||Bausch Health Cos., Inc.||0.25%||28.50||0.0%||$46.49m|
|AXSM||Axsome Therapeutics, Inc.||-1.28%||40.10||1.8%||$41.54m|
|PCRX||Pacira Biosciences, Inc.||-1.19%||53.20||9.8%||$32.21m|
|ENDP||Endo International Plc||0.73%||4.17||8.5%||$31.75m|
|INDP||Indaptus Therapeutics, Inc.||-0.51%||7.80||0.0%||$27.93m|
Regulus Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The firm is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded on September 5, 2007 and is headquartered in San Diego, CA.